Outlook Therapeutics IncNASDAQ:OTLK
- LAST PRICE5.0300
- TODAY'S CHANGE (%)-0.1000 (-1.9493%)
- Bid / Lots5.0200/ 1
- Ask / Lots5.4600/ 8
- Open / Previous Close5.1400 / 5.1300
- Day Range
- 52 Week Range
- Volume329,960
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OTLK |
|---|---|---|
| 09:32 ET | 1543 | 5.12 |
| 09:33 ET | 269 | 5.145 |
| 09:39 ET | 875 | 5.15 |
| 09:44 ET | 100 | 5.22 |
| 09:46 ET | 3770 | 5.1 |
| 09:48 ET | 200 | 5.1 |
| 09:50 ET | 893 | 5.1 |
| 09:51 ET | 100 | 5.1 |
| 09:53 ET | 500 | 5.0999 |
| 09:55 ET | 4934 | 5.095 |
| 09:57 ET | 300 | 5.08 |
| 10:00 ET | 200 | 5.09 |
| 10:02 ET | 282 | 5.08 |
| 10:06 ET | 100 | 5.07 |
| 10:08 ET | 1100 | 5.1 |
| 10:11 ET | 200 | 5.1 |
| 10:13 ET | 1600 | 5.1 |
| 10:15 ET | 2787 | 5.1 |
| 10:20 ET | 4009 | 5.1 |
| 10:24 ET | 1532 | 5.09 |
| 10:26 ET | 1400 | 5.078 |
| 10:29 ET | 5133 | 5.03 |
| 10:31 ET | 11024 | 5.02 |
| 10:33 ET | 4293 | 5.03 |
| 10:36 ET | 2115 | 5.02 |
| 10:38 ET | 4683 | 5.015 |
| 10:40 ET | 2723 | 5.02 |
| 10:42 ET | 3450 | 5.06 |
| 10:44 ET | 600 | 5.06 |
| 10:47 ET | 600 | 5.1 |
| 10:51 ET | 127 | 5.08 |
| 10:58 ET | 1000 | 5.1 |
| 11:00 ET | 100 | 5.1 |
| 11:03 ET | 415 | 5.08 |
| 11:05 ET | 250 | 5.09 |
| 11:07 ET | 200 | 5.08 |
| 11:09 ET | 100 | 5.095 |
| 11:12 ET | 991 | 5.1 |
| 11:14 ET | 300 | 5.0999 |
| 11:18 ET | 1058 | 5.0901 |
| 11:20 ET | 2960 | 5.0966 |
| 11:21 ET | 1701 | 5.095 |
| 11:23 ET | 300 | 5.1 |
| 11:25 ET | 200 | 5.1 |
| 11:27 ET | 705 | 5.1 |
| 11:30 ET | 100 | 5.1 |
| 11:32 ET | 400 | 5.1 |
| 11:34 ET | 13903 | 5.09 |
| 11:36 ET | 3754 | 5.085 |
| 11:38 ET | 382 | 5.105 |
| 11:39 ET | 100 | 5.115 |
| 11:43 ET | 620 | 5.15 |
| 12:03 ET | 100 | 5.135 |
| 12:08 ET | 700 | 5.14 |
| 12:12 ET | 100 | 5.13 |
| 12:14 ET | 100 | 5.14 |
| 12:15 ET | 3518 | 5.09 |
| 12:17 ET | 200 | 5.08 |
| 12:26 ET | 600 | 5.06 |
| 12:28 ET | 100 | 5.065 |
| 12:30 ET | 400 | 5.06 |
| 12:32 ET | 2066 | 5.049 |
| 12:33 ET | 800 | 5.05 |
| 12:35 ET | 900 | 5.05 |
| 12:37 ET | 600 | 5.055 |
| 12:39 ET | 924 | 5.07 |
| 12:42 ET | 300 | 5.0748 |
| 12:44 ET | 393 | 5.08 |
| 12:46 ET | 1400 | 5.0974 |
| 12:48 ET | 899 | 5.09 |
| 12:50 ET | 300 | 5.095 |
| 12:51 ET | 711 | 5.1 |
| 12:57 ET | 200 | 5.095 |
| 01:00 ET | 947 | 5.0844 |
| 01:02 ET | 100 | 5.08 |
| 01:04 ET | 100 | 5.085 |
| 01:06 ET | 200 | 5.09 |
| 01:09 ET | 400 | 5.08 |
| 01:11 ET | 400 | 5.095 |
| 01:13 ET | 100 | 5.1 |
| 01:15 ET | 209 | 5.095 |
| 01:18 ET | 100 | 5.097 |
| 01:20 ET | 1941 | 5.1 |
| 01:22 ET | 13834 | 5.1 |
| 01:24 ET | 4300 | 5.1 |
| 01:26 ET | 1964 | 5.09 |
| 01:27 ET | 1233 | 5.1 |
| 01:29 ET | 100 | 5.0831 |
| 01:31 ET | 200 | 5.08 |
| 01:33 ET | 100 | 5.09 |
| 01:36 ET | 616 | 5.09 |
| 01:38 ET | 300 | 5.09 |
| 01:40 ET | 300 | 5.08 |
| 01:42 ET | 700 | 5.08 |
| 01:45 ET | 2390 | 5.05 |
| 01:47 ET | 100 | 5.06 |
| 01:49 ET | 3962 | 5.0383 |
| 01:51 ET | 600 | 5.05 |
| 01:56 ET | 612 | 5.04 |
| 01:58 ET | 2600 | 5.0599 |
| 02:00 ET | 200 | 5.05 |
| 02:03 ET | 200 | 5.07 |
| 02:05 ET | 100 | 5.06 |
| 02:09 ET | 927 | 5.1 |
| 02:14 ET | 1000 | 5.0966 |
| 02:18 ET | 247 | 5.09 |
| 02:20 ET | 100 | 5.095 |
| 02:23 ET | 1905 | 5.155 |
| 02:25 ET | 400 | 5.17 |
| 02:30 ET | 100 | 5.17 |
| 02:34 ET | 638 | 5.15 |
| 02:38 ET | 400 | 5.17 |
| 02:39 ET | 2191 | 5.23 |
| 02:41 ET | 1680 | 5.225 |
| 02:43 ET | 875 | 5.21 |
| 02:45 ET | 850 | 5.21 |
| 02:48 ET | 100 | 5.21 |
| 02:54 ET | 569 | 5.208 |
| 02:56 ET | 1108 | 5.175 |
| 02:57 ET | 625 | 5.17 |
| 03:01 ET | 100 | 5.15 |
| 03:03 ET | 467 | 5.1539 |
| 03:08 ET | 100 | 5.15 |
| 03:10 ET | 600 | 5.15 |
| 03:12 ET | 716 | 5.15 |
| 03:14 ET | 535 | 5.19 |
| 03:15 ET | 3675 | 5.15 |
| 03:19 ET | 10284 | 5.16 |
| 03:21 ET | 728 | 5.13 |
| 03:24 ET | 100 | 5.135 |
| 03:26 ET | 500 | 5.14 |
| 03:32 ET | 707 | 5.13 |
| 03:33 ET | 700 | 5.12 |
| 03:37 ET | 1186 | 5.11 |
| 03:42 ET | 7399 | 5.1 |
| 03:44 ET | 2100 | 5.105 |
| 03:46 ET | 7745 | 5.1199 |
| 03:48 ET | 6618 | 5.08 |
| 03:50 ET | 200 | 5.08 |
| 03:51 ET | 1991 | 5.09 |
| 03:53 ET | 3009 | 5.09 |
| 03:55 ET | 18261 | 5.065 |
| 03:57 ET | 1957 | 5.035 |
| 04:00 ET | 43648 | 5.03 |
Nov 6, 2024
Outlook Therapeutics(R) to Present at the Guggenheim Healthcare Innovation Conference, from 8:05AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:05AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Outlook Therapeutics Inc | 121.4M | -0.6x | --- |
Ventyx Biosciences Inc | 122.3M | -0.8x | --- |
Vigil Neuroscience Inc | 122.6M | -1.5x | --- |
Invizyne Technologies Inc | 117.8M | -23.6x | --- |
Pyxis Oncology Inc | 124.9M | -1.8x | --- |
Skye Bioscience Inc | 126.5M | -4.9x | --- |
Company Information
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Contact Information
- Headquarters
- 111 S. Wood Avenue, Unit #100ISELIN, NJ, United States 08830
- Phone
- 609-619-3990
- Fax
- ---
Executives
- Independent Executive Chairman of the Board
- Ralph Thurman
- President, Chief Executive Officer, Director
- C. Russell Trenary
- Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
- Lawrence Kenyon
- Senior Vice President - Head of Europe
- Jedd Comiskey
- Senior Vice President - Licensing and M&A
- Joel Prieve
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $121.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-8.12 |
Book Value | $-1.11 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
